Skip Navigation

European Heart Journal 2004 25(11):997; doi:10.1016/j.ehj.2004.04.002
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Merckx, K.L
Right arrow Articles by Crijns, H.J.G.M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Merckx, K.L
Right arrow Articles by Crijns, H.J.G.M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letter to the Editor

Cardioversion threshold, IRAF and beyond

K.L Merckx, R.G Tieleman and H.J.G.M Crijns*

Department of Cardiology, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands

* Tel.: +31-433-875-093; fax: +31-433-875-104
E-mail address: hcri@cardio.azm.nl

The first 10% of the full text of this article appears below.

We read with great interest the report of De Simone et al. in the August 2003 issue of the journal.1 The main finding of their study was that verapamil, added to flecainide or amiodarone . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?